BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22441997)

  • 1. [NASH (non-alcoholic steatohepatitis): fatty liver or fatal liver disease?].
    Roeb E
    Zentralbl Chir; 2014 Apr; 139(2):168-74. PubMed ID: 22441997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
    Pár A; Pár G
    Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
    Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of fatty liver disease with the metabolic syndrome.
    Machado MV; Cortez-Pinto H
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):487-500. PubMed ID: 24665862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis.
    Kanwar P; Kowdley KV
    Clin Liver Dis; 2016 May; 20(2):225-43. PubMed ID: 27063266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-alcoholic fatty liver disease and steatohepatitis].
    Pár G; Horváth G; Pár A
    Orv Hetil; 2013 Jul; 154(29):1124-34. PubMed ID: 23853345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Yopp AC; Choti MA
    Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
    Lazaridis N; Tsochatzis E
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
    Tiniakos DG
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):643-50. PubMed ID: 19478676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome.
    El Atrache MM; Abouljoud MS; Divine G; Yoshida A; Kim DY; Kazimi MM; Moonka D; Huang MA; Brown K
    Clin Transplant; 2012; 26(5):E505-12. PubMed ID: 23061759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.